We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Reasons to Add Fresenius Medical Stock to Your Portfolio Now
Read MoreHide Full Article
Key Takeaways
Fresenius Medical is benefiting from strategic acquisitions, partnerships, and a growing global footprint.
Fresenius Medical projects 30.1% earnings growth in 2025, with estimates up 15 cents over the past 90 days.
FMS's FME25 program delivered EUR 68 million in the first quarter savings.
Fresenius Medical Care AG & Co. (FMS - Free Report) is well-poised for growth on the back of strategic acquisitions and partnerships and a solid global foothold. However, a tough regulatory environment remains a concern.
Shares of this Zacks Rank #2 (Buy) company have risen 25.1% year to date against the industry’s decline of 9.1%. The S&P 500 Index has increased 0.9% in the same time frame.
The company, with a market capitalization of $16.64 billion, is one of the largest integrated providers of products and services for individuals undergoing dialysis following chronic kidney failure. Its bottom line is anticipated to improve 9.6% over the next five years. FMS’ earnings beat estimates in all the trailing four quarters, delivering an average surprise of 6.6%.
Image Source: Zacks Investment Research
Reasons Favoring FMS’s Growth
Strategic Acquisitions & Partnerships: Fresenius Medical has leveraged strategic acquisitions and partnerships to drive its growth strategy. It acquired NxStage Medical for $30 per share, expecting earnings accretion within three years and annual pre-tax savings of $80 million to $100 million. The company’s 2025 growth strategy includes the merger of Fresenius Health Partners, InterWell Health, and Cricket Health to manage 270,000 patients with kidney disease and $11 billion in associated medical costs. Additionally, it expanded its home dialysis market through a distribution deal with JMS Co. Ltd. in Japan and extended agreements with DaVita and Aetna to enhance patient access to home hemodialysis and value-based care.
Strong Global Foothold: Fresenius Medical has a strong global presence across North America, Europe (EMEA), the Asia Pacific, and Latin America, expanding through organic growth and strategic acquisitions. It entered the dialysis market in Israel and strengthened its foothold in India by acquiring an 85% stake in Sandor Nephro Services. The company also focuses on public-private partnerships to tap into new markets. Despite pandemic challenges, it has maintained steady organic growth, with significant contributions from EMEA, Asia Pacific, and Latin America, particularly in the third quarter of 2024.
Strong Q1 Results: FMS exited the first quarter on a mixed note, with its earnings and revenues surpassing and missing their respective Zacks Consensus Estimate. Overall pricing momentum also supported growth in the Care Enablement segment.
Per management, during the first quarter, the FME25 transformation program continued its positive momentum, delivering EUR 68 million additional sustainable savings while related one-time costs, treated as special items, amounted to EUR 28 million. The company confirmed its full-year target of around EUR 180 million in additional annual savings, totaling EUR 750 million by 2025-end.
The company’s continued divestment of its non-core and dilutive assets appears promising, as it will help focus on its core and growing categories, while also boosting its cash resources.
A Factor That May Offset FMS’s Gains
Tough Regulatory Environment: Fresenius Medical operates in a highly regulated environment, facing strict legal and antitrust requirements across countries. Non-compliance can result in severe penalties, loss of certifications, product recalls, or even business restrictions. Regulatory changes, especially in reimbursement policies, could impact its business model and strategy. Additionally, international exposure presents challenges in enforcing trade receivables, with some countries' debt issues posing potential risks. While short-term regulatory risks remain low, they could become a medium-term concern.
Estimate Trend
The Zacks Consensus Estimate for 2025 revenues is pegged at $21.84 billion, indicating 4.4% year-over-year growth. The consensus mark for earnings is pinned at $2.16 per share, implying growth of 30.1% from the year-ago level. The earnings estimates have improved 15 cents in the past 90 days.
Other Key Picks
Some other top-ranked stocks in the broader medical space that have announced quarterly results are CVS Health Corporation (CVS - Free Report) , Integer Holdings Corporation (ITGR - Free Report) and AngioDynamics (ANGO - Free Report) .
Revenues of $94.59 billion outpaced the consensus mark by 1.8%. CVS Health has a long-term estimated growth rate of 11.4%. Its earnings surpassed estimates in each of the trailing four quarters, with an average surprise of 18.1%.
Integer Holdings reported first-quarter 2025 adjusted EPS of $1.31, beating the Zacks Consensus Estimate by 3.2%. Revenues of $437.4 million surpassed the Zacks Consensus Estimate by 1.3%. It currently sports a Zacks Rank of 1.
Integer Holdings has a long-term estimated growth rate of 18.4%. ITGR’s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 2.8%.
AngioDynamics, currently sporting a Zacks Rank #1, reported a third-quarter fiscal 2025 adjusted EPS of 3 cents against the Zacks Consensus Estimate of a 13-cent loss. Revenues of $72 million beat the Zacks Consensus Estimate by 2%.
ANGO has an estimated fiscal 2026 earnings growth rate of 27.8% compared with the S&P 500 Composite’s 10.5% growth. AngioDynamics’ earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 70.9%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Reasons to Add Fresenius Medical Stock to Your Portfolio Now
Key Takeaways
Fresenius Medical Care AG & Co. (FMS - Free Report) is well-poised for growth on the back of strategic acquisitions and partnerships and a solid global foothold. However, a tough regulatory environment remains a concern.
Shares of this Zacks Rank #2 (Buy) company have risen 25.1% year to date against the industry’s decline of 9.1%. The S&P 500 Index has increased 0.9% in the same time frame.
The company, with a market capitalization of $16.64 billion, is one of the largest integrated providers of products and services for individuals undergoing dialysis following chronic kidney failure. Its bottom line is anticipated to improve 9.6% over the next five years. FMS’ earnings beat estimates in all the trailing four quarters, delivering an average surprise of 6.6%.
Image Source: Zacks Investment Research
Reasons Favoring FMS’s Growth
Strategic Acquisitions & Partnerships: Fresenius Medical has leveraged strategic acquisitions and partnerships to drive its growth strategy. It acquired NxStage Medical for $30 per share, expecting earnings accretion within three years and annual pre-tax savings of $80 million to $100 million. The company’s 2025 growth strategy includes the merger of Fresenius Health Partners, InterWell Health, and Cricket Health to manage 270,000 patients with kidney disease and $11 billion in associated medical costs. Additionally, it expanded its home dialysis market through a distribution deal with JMS Co. Ltd. in Japan and extended agreements with DaVita and Aetna to enhance patient access to home hemodialysis and value-based care.
Strong Global Foothold: Fresenius Medical has a strong global presence across North America, Europe (EMEA), the Asia Pacific, and Latin America, expanding through organic growth and strategic acquisitions. It entered the dialysis market in Israel and strengthened its foothold in India by acquiring an 85% stake in Sandor Nephro Services. The company also focuses on public-private partnerships to tap into new markets. Despite pandemic challenges, it has maintained steady organic growth, with significant contributions from EMEA, Asia Pacific, and Latin America, particularly in the third quarter of 2024.
Strong Q1 Results: FMS exited the first quarter on a mixed note, with its earnings and revenues surpassing and missing their respective Zacks Consensus Estimate. Overall pricing momentum also supported growth in the Care Enablement segment.
Per management, during the first quarter, the FME25 transformation program continued its positive momentum, delivering EUR 68 million additional sustainable savings while related one-time costs, treated as special items, amounted to EUR 28 million. The company confirmed its full-year target of around EUR 180 million in additional annual savings, totaling EUR 750 million by 2025-end.
The company’s continued divestment of its non-core and dilutive assets appears promising, as it will help focus on its core and growing categories, while also boosting its cash resources.
A Factor That May Offset FMS’s Gains
Tough Regulatory Environment: Fresenius Medical operates in a highly regulated environment, facing strict legal and antitrust requirements across countries. Non-compliance can result in severe penalties, loss of certifications, product recalls, or even business restrictions. Regulatory changes, especially in reimbursement policies, could impact its business model and strategy. Additionally, international exposure presents challenges in enforcing trade receivables, with some countries' debt issues posing potential risks. While short-term regulatory risks remain low, they could become a medium-term concern.
Estimate Trend
The Zacks Consensus Estimate for 2025 revenues is pegged at $21.84 billion, indicating 4.4% year-over-year growth. The consensus mark for earnings is pinned at $2.16 per share, implying growth of 30.1% from the year-ago level. The earnings estimates have improved 15 cents in the past 90 days.
Other Key Picks
Some other top-ranked stocks in the broader medical space that have announced quarterly results are CVS Health Corporation (CVS - Free Report) , Integer Holdings Corporation (ITGR - Free Report) and AngioDynamics (ANGO - Free Report) .
CVS Health, carrying a Zacks Rank of 2, reported first-quarter 2025 adjusted EPS of $2.25, beating the Zacks Consensus Estimate by 31.6%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Revenues of $94.59 billion outpaced the consensus mark by 1.8%. CVS Health has a long-term estimated growth rate of 11.4%. Its earnings surpassed estimates in each of the trailing four quarters, with an average surprise of 18.1%.
Integer Holdings reported first-quarter 2025 adjusted EPS of $1.31, beating the Zacks Consensus Estimate by 3.2%. Revenues of $437.4 million surpassed the Zacks Consensus Estimate by 1.3%. It currently sports a Zacks Rank of 1.
Integer Holdings has a long-term estimated growth rate of 18.4%. ITGR’s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 2.8%.
AngioDynamics, currently sporting a Zacks Rank #1, reported a third-quarter fiscal 2025 adjusted EPS of 3 cents against the Zacks Consensus Estimate of a 13-cent loss. Revenues of $72 million beat the Zacks Consensus Estimate by 2%.
ANGO has an estimated fiscal 2026 earnings growth rate of 27.8% compared with the S&P 500 Composite’s 10.5% growth. AngioDynamics’ earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 70.9%.